Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03874832 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
A Phase 1 study of Migraine and Migraine With Aura, sponsored by Satsuma Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT03874832: Completed Phase 1 study of Migraine and Migraine With Aura, sponsored by Satsuma Pharmaceuticals.
NCT03874832 is a Phase 1 study of Migraine and Migraine With Aura that has completed, run by Satsuma Pharmaceuticals. The registered enrollment target is 46 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03874832, a Phase 1 study of Migraine and Migraine With Aura, has completed, sponsored by Satsuma Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
Single-center, single-dose, open-label, 2-part, 3-period crossover (in each part), pharmacokinetic and safety study.
Primary Outcome
To select a dose level of STS101 for further evaluation in Part 2
Conditions Studied
Interventions
- DRUG Dihydroergotamine
Study Locations (1)
Florida
- Quotient Sciences Miami Inc. - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2018-09-11 |
| Est. Completion | 2018-11-07 |
| Phase | Phase 1 |
What the finished NCT03874832 record still lists
NCT03874832 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (87% lower).
The record links to 3 conditions, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which Dihydroergotamine is the first listed.
NCT03874832 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT03874832 about?
NCT03874832 is a clinical study titled "A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects". Single-center, single-dose, open-label, 2-part, 3-period crossover (in each part), pharmacokinetic and safety study.
What is the current status of trial NCT03874832?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2018-09-11. Estimated completion is 2018-11-07.
What conditions does trial NCT03874832 study?
This clinical trial studies the following conditions: Migraine, Migraine With Aura, Migraine Without Aura.
What interventions are being tested in trial NCT03874832?
The interventions under investigation include: Dihydroergotamine (DRUG).
Who is sponsoring clinical trial NCT03874832?
This trial is sponsored by Satsuma Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03874832 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03874832's enrollment target sits among peer trials
46 85th of 102 higher than 18 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants
COMPLETED · Phase 1
-
Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults
COMPLETED · Phase 1
-
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
COMPLETED · Phase 1
-
A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants
COMPLETED · Phase 1
-
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
COMPLETED · Phase 1
-
Migraine Manager (R01)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI